网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
T2DM合并NAFLD:分子机制及治疗研究进展
作者:项丹 王尧 
单位:东南大学
关键词:2型糖尿病 非酒精性脂肪性肝病 细胞因子 胰岛素抵抗 
分类号:
出版年·卷·期(页码):2013·41·第九期(684-690)
摘要:

目前糖尿病和脂肪肝的发病已呈全球流行的趋势,且逐年递增,而2型糖尿病(T2DM)患者中非酒精性脂肪肝(NAFLD)的发病明显高于正常人群。高脂高热量饮食、多坐少动的生活方式、胰岛素抵抗、2型糖尿病、代谢综合征及其组分都是增加NAFLD发病的危险因素。胰岛素抵抗是T2DM合并NAFLD的病理学基础。肿瘤坏死因子、抵抗素、脂联素、瘦素、网膜素、内脏脂联素等细胞因子参与胰岛素抵抗,并在T2DM合并NAFLD的发生发展中起重要作用。控制体重、健康饮食、改善胰岛素抵抗是治疗NAFLD的原则,其中控制体重作为治疗原则的首选。

Diabetes and fatty liver disease increasing year by year has shown a trend of the global epidemic, and the incidence of type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD) is significantly higher than the normal population. High-fat high-calorie diet, and more sit sedentary lifestyle, insulin resistance, type 2 diabetes, metabolic syndrome and its components are increased risk factors for NAFLD incidence. Insulin resistance is the basis of the pathology of T2DM with NAFLD. Cytokines like tumor necrosis factor, resistin, adiponectin, leptin, retinal pigment ,visceral fat adiponectin are involved in insulin resistance, and play an important role in the occurrence and development of T2DM with NAFLD. Weight control, healthy diet, improve insulin resistance is the principle of treatment of NAFLD, including weight control as the preferred treatment principles.

参考文献:
服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 752147 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541